Chemours (NYSE:CC) Stock Gets Price Target Cut from UBS Group

Chemours (NYSE:CC) had its price objective trimmed by UBS Group from $16.00 to $15.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a neutral rating on the specialty chemicals company’s stock.

Several other research analysts have also recently issued reports on the company. Barclays initiated coverage on Chemours in a research report on Monday, October 12th. They set an “equal weight” rating and a $16.00 target price on the stock. Royal Bank Of Canada cut shares of Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 target price on the stock. in a research report on Tuesday, October 13th. JPMorgan Chase & Co. cut their price target on shares of Chemours from $22.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 13th. Morgan Stanley set a $18.00 target price on Chemours in a research note on Monday, August 10th. Finally, BMO Capital Markets dropped their price target on shares of Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a research note on Thursday, August 13th. Three investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $17.45.

Chemours Trading Down 0.2%

Shares of CC stock traded down $0.03 during mid-day trading on Wednesday, reaching $12.72. 3,698,087 shares of the stock traded hands, compared to its average volume of 2,310,033. The company has a market cap of $1.91 billion, a price-to-earnings ratio of -12.47 and a beta of 1.47. The company has a quick ratio of 0.88, a current ratio of 1.66 and a debt-to-equity ratio of 18.98. The stock’s fifty day simple moving average is $13.96 and its two-hundred day simple moving average is $18.22. Chemours has a 1-year low of $10.44 and a 1-year high of $28.67.

Chemours (NYSE:CC) last issued its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). Chemours had a negative net margin of 2.64% and a positive return on equity of 78.76%. The business had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter last year, the business earned $0.40 EPS. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. On average, research analysts anticipate that Chemours will post 0.82 EPS for the current fiscal year.

Chemours Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be given a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, November 16th. Chemours’s dividend payout ratio (DPR) is -34.31%.

Insider Activity at Chemours

In other Chemours news, insider Calderon Gerardo Familiar bought 1,935 shares of Chemours stock in a transaction that occurred on Wednesday, August 12th. The stock was acquired at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the transaction, the insider directly owned 58,547 shares in the company, valued at $909,234.91. This represents a 3.42% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Denise Dignam bought 3,378 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was acquired at an average price of $14.95 per share, for a total transaction of $50,501.10. Following the completion of the purchase, the chief executive officer directly owned 339,916 shares in the company, valued at approximately $5,081,744.20. The trade was a 1.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.85% of the stock is currently owned by insiders.

Institutional Trading of Chemours

Large investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. bought a new position in shares of Chemours in the second quarter worth approximately $34,000. Allworth Financial LP purchased a new position in Chemours in the 2nd quarter worth approximately $51,000. State of Wyoming bought a new stake in Chemours in the second quarter valued at approximately $67,000. Nykredit A S bought a new stake in Chemours in the second quarter valued at approximately $99,000. Finally, Sterling Capital Management LLC boosted its stake in shares of Chemours by 839.3% during the third quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock valued at $69,000 after purchasing an additional 4,532 shares during the period. Institutional investors own 76.26% of the company’s stock.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions aimed at managing heat in AI data centers, with the company touting improved efficiency and lower water use. The product could help it benefit from growing data-center demand. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
• Neutral Sentiment: Barclays maintained its Hold rating. Other analyst views are mixed, while UBS lowered its price target to $15 and kept a Neutral rating. Article: Barclays Keeps Their Hold Rating on Chemours
• Negative Sentiment: Zacks Research downgraded CC from Hold to Strong Sell, adding to concerns about analyst sentiment. Zacks Research rating information
• Negative Sentiment: Multiple law firms publicized a securities class action filed against Chemours and certain officers, covering purchases from February 20 through August 4, 2026. The suit alleges securities-law violations, including claims related to 2026 EBITDA guidance and refrigerant sales pulled forward by customer prebuying; these allegations have not been proven. Investors have until December 7 to seek lead-plaintiff status. The repeated alerts concern the same case, rather than separate lawsuits. Article: Lawsuit deadline and allegations regarding 2026 EBITDA guidance

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.